Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis
- 394 Downloads
The role of gastritis in dyspepsia remains controversial. We aimed to examine the efficacy of rebamipide, a gastric mucosal protective agent, in both organic and functional dyspepsia.
A systematic review and meta-analysis was performed. The following databases were searched using the keywords (“rebamipide” OR “gastroprotective agent*” OR “mucosta”) AND (“dyspepsia” OR “indigestion” OR “gastrointestinal symptoms”): PubMed, Wed of Science, Embase, CINAHL, Cochrane Clinical Trials Register. The primary outcome was dyspepsia or upper GI symptom score improvement. Pooled analysis of the main outcome data were presented as risk ratio (RR) for dichotomous data and standardized mean difference (SMD) for continuous data.
From an initial 248 records, 17 randomised controlled trial (RCT) publications involving 2170 subjects (1224 rebamipide, 946 placebo/control) were included in the final analysis. Twelve RCTs were conducted in subjects with organic dyspepsia (peptic ulcer disease, reflux esophagitis or NSAID-induced gastropathy) and five RCTs were conducted in patients with functional dyspepsia (FD). Overall, dyspepsia symptom improvement was significantly better with rebamipide compared to placebo/control drug (RR 0.77, 95% CI = 0.64–0.93; SMD −0.46, 95% CI = −0.83 to −0.09). Significant symptom improvement was observed both in pooled RR and SMD in subjects with organic dyspepsia (RR 0.72, 95% CI = 0.61–0.86; SMD −0.23, 95% CI = −0.4 to −0.07), while symptom improvement in FD was observed in pooled SMD but not RR (SMD −0.62, 95% CI = −1.16 to −0.08; RR 1.01, 95% CI = 0.71–1.45).
Rebamipide is effective in organic dyspepsia and may improve symptoms in functional dyspepsia.
KeywordsRebamipide Gastritis Dyspepsia NSAID gastropathy Meta-analysis
MPT was a recipient of a University of Malaya Grand Challenge fund which also funded the salary of MHJ (GC002-14HTM).
SM planned the study, contributed to data collection, and drafted the manuscript. MHJ and SZS performed data collection and preliminary data analysis. MPT planned the study and performed data collection. SR performed final data analysis and contributed to the drafting of the manuscript. All authors agreed on the final draft of the manuscript.
Compliance with ethical standards
Conflict of interest
The authors declared that they have no conflicts of interest.
- 3.Ford AC, Marwaha A, Lim A, et al. What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia? Systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2010;8:830-7–837e1-2.Google Scholar
- 20.Syam AH, Simadibrata M, Rani A, et al. Rebamipide effect on chronic gastritis in dyspeptic patient: symptoms, endoscopic and histological evaluation. Digestion. 2012;85:156.Google Scholar
- 27.Rew JS, Joo YE, Kim HS, et al. Efficacy of rebamipide maintenance therapy after eradication of Helicobacter pylori infection in patients with chronic gastritis or gastric ulcer. Kor J Gastroenterol. 2000;36:175–184.Google Scholar
- 29.Hasegawa M, Horiki N, Tanaka K, et al. The efficacy of rebamipide add-on therapy in arthritic patients with COX-2 selective inhibitor-related gastrointestinal events: a prospective, randomized, open-label blinded-endpoint pilot study by the GLORIA study group. Mod Rheumatol. 2013;23:1172–1178.CrossRefPubMedGoogle Scholar
- 38.Seearamroongruang T, Chunlertrith K, Mairiang P, et al. Effect of rebamipide combined with omeprazole on symptom improvement in non-helicobacter pylori gastritis. Thai J Gastroenterol. 2009;10:82–90.Google Scholar